全文获取类型
收费全文 | 74648篇 |
免费 | 6645篇 |
国内免费 | 2870篇 |
专业分类
耳鼻咽喉 | 690篇 |
儿科学 | 1826篇 |
妇产科学 | 1309篇 |
基础医学 | 7115篇 |
口腔科学 | 1161篇 |
临床医学 | 6962篇 |
内科学 | 6227篇 |
皮肤病学 | 805篇 |
神经病学 | 2344篇 |
特种医学 | 3550篇 |
外国民族医学 | 60篇 |
外科学 | 14064篇 |
综合类 | 12254篇 |
现状与发展 | 20篇 |
预防医学 | 1926篇 |
眼科学 | 607篇 |
药学 | 5110篇 |
51篇 | |
中国医学 | 2082篇 |
肿瘤学 | 16000篇 |
出版年
2024年 | 215篇 |
2023年 | 1137篇 |
2022年 | 2369篇 |
2021年 | 3168篇 |
2020年 | 2611篇 |
2019年 | 2371篇 |
2018年 | 2221篇 |
2017年 | 2520篇 |
2016年 | 2701篇 |
2015年 | 2997篇 |
2014年 | 4631篇 |
2013年 | 4680篇 |
2012年 | 4102篇 |
2011年 | 4677篇 |
2010年 | 3838篇 |
2009年 | 3813篇 |
2008年 | 3745篇 |
2007年 | 3965篇 |
2006年 | 3691篇 |
2005年 | 3259篇 |
2004年 | 2834篇 |
2003年 | 2412篇 |
2002年 | 2216篇 |
2001年 | 1967篇 |
2000年 | 1562篇 |
1999年 | 1386篇 |
1998年 | 1204篇 |
1997年 | 1102篇 |
1996年 | 943篇 |
1995年 | 845篇 |
1994年 | 746篇 |
1993年 | 562篇 |
1992年 | 481篇 |
1991年 | 395篇 |
1990年 | 332篇 |
1989年 | 307篇 |
1988年 | 303篇 |
1987年 | 264篇 |
1986年 | 193篇 |
1985年 | 248篇 |
1984年 | 226篇 |
1983年 | 145篇 |
1982年 | 179篇 |
1981年 | 140篇 |
1980年 | 109篇 |
1979年 | 108篇 |
1978年 | 87篇 |
1977年 | 50篇 |
1976年 | 45篇 |
1975年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
891.
Tsukasa Ohnishi Kiyoshi Mori Sei Ohta Kohei Yokoi Naoto Miyazawa Keigo Tominaga Mitsuru Adachi 《International journal of clinical oncology / Japan Society of Clinical Oncology》1997,2(4):235-237
Tumor lysis syndrome is a rare complication of nonhematologic malignancies that results from massive necrosis of neoplastic
cells after chemotherapy. This syndrome consists of life-threatening metabolic derangements, including severe hyperphosphatemia,
hyperkalemia, hyperuricemia, and hypocalcemia, and may result in renal failure and death if not recognized early and treated
appropriately. We report a case of tumor lysis syndrome after induction chemotherapy in a patient with widely metastatic smallcell
lung cancer. This case emphasizes the importance of awareness and early treatment of this syndrome. 相似文献
892.
恶性胸腹水自体蛋白的制备及回输 总被引:8,自引:1,他引:8
恶性肿瘤晚期患者常并发胸腹水,胸腹水里含有大量可溶性蛋白,蛋白浓度约为40mg/ml,其中白蛋白占50%以上,球蛋白占20%左右。本实验室比较了4种不同的分离纯化胸腹水蛋白的方法,其中离心滤过的方法能彻底除去细胞成分,特别是肿瘤细胞,而且蛋白回收率高,操作简单,不参入外源物质,我们采用该方法将恶性胸腹水中的蛋白回收,并回输给患者,临床应用27例次,取得了较好的临床效果。 相似文献
893.
目的:观察中药抗癌宝口服液治疗中晚期恶性肿瘤临床效果。方法:103例患者随机分为抗癌宝观察组与化疗对照组,对两组疗效作比较。结果:观察组患者免疫功能,近期有效率(CR+PR),生存质量,1、2、3年生存期及中位生存时间,癌胚抗原下降水平,明显高于对照组,且有显著性差异。结论:抗癌宝具有抑制肿瘤生长,延长生存时间,提高生存质量之效。 相似文献
894.
Koichiro Matsukado Shin Nakano Raymond T. Bartus Keith L. Black 《Journal of neuro-oncology》1997,34(2):131-138
A blood-tumor barrier (BTB) limits delivery of antitumoragents to brain tumors. This study sought todetermine whether dexamethasone (DXN) treatment of rats withintracranial gliomas would 1) further impair delivery ofcarboplatin to brain tumors, and 2) whether intracarotidinfusion of the bradykinin analog, RMP-7, would improvedelivery during concurrent DXN treatment. Wistar rats withRG2 gliomas were utilized and a unidirectional transport,Ki, of radiolabeled [14C] carboplatin was determined usingquantitative autoradiography. In DXN pretreatment animals, 3 mg/kg/dayof DXN was administered intraperitoneally for 3 daysprior to Ki determinations. At 10 days aftertumor implantation, Ki of [14C] carboplatin into DXN-treatedtumors and brain surrounding tumor (BST) was significantlylower compared to non-DXN treated tumors and BST(3.30 ± 0.91 vs. 4.47 ± 1.80, p< 0.05, and 0.94 ± 0.84 vs. 2.18± 0.79, p < 0.05, respectively). Intracarotid infusionof RMP-7 (0.1 mg/kg/min) significantly increased the Kifor carboplatin in DXN-treated tumors (6.35 ± 3.10vs. 3.30 ± 0.91, p < 0.01), however, RMP-7increased Ki to a greater extent in tumorsnot pretreated with DXN (12.07 ± 3.60 vs.4.47 ± 1.80, p < 0.0001). Our studiesshow that dexamethasone decreases transport of carboplatin intobrain tumors. Intracarotid infusion of RMP-7 selectively increasescarboplatin transport to tumors. 相似文献
895.
Immunotherapy I: Cytokine gene transfer strategies 总被引:2,自引:0,他引:2
The cytokine approach to gene therapy of cancer stems from early studies of direct, repeated injection of recombinant cytokines at the tumor site, and extension of the bystander effect that enables a few cytokine gene transduced cells in a tumor to bring about its total destruction. This effect can be extended through the immune system, since cytokine-activated regression of a small mass of tumor cells can afford systemic protection. Transduced cells used as a vaccine provide a local concentration of both cytokine and tumor antigens. Cytokines sustain antigen uptake and presentation by increasing the immunogenic potential of the environment through the recruitment of antigen presenting cells and leukocytes, and activation of a cascade of events which amplify and tone up the efficacy of a vaccine. The promises and difficulties of this approach are discussed by considering what is still missing from experimental studies and what can best be done as soon as possible in animals and humans to reach compelling conclusions. 相似文献
896.
升白冲剂治疗恶性肿瘤化疗后血细胞减少症的临床观察 总被引:5,自引:0,他引:5
用升白冲剂(治疗组)与升白细胞西药(对照组)治疗恶性肿瘤化疗后血细胞减少症238例,结果:治疗组升高血细胞总有效率明显高于对照组,P<0.01,且治疗组还能减轻化疗病人的毒副作用。 相似文献
897.
世界中西医结合大会在京召开──交流中西医结合在理论、临床、教育及政策管理方面经验人民日报北京10月27日讯世界中西医结合大会今天在北京国际会议中心开幕。大会以“继承、发扬、结合、创新”为主题,交流重点是中西医结合在理论、临床、教育及政策管理等各方面的... 相似文献
898.
Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo 总被引:2,自引:0,他引:2
Yogendra Singh Nobuaki Shikata Yasuhiko Kiyozuka Hiroyuki Nambu Junji Morimoto Junichi Kurebayashi Koshiro Hioki Airo Tsubura 《Breast cancer research and treatment》1997,45(1):15-27
Antitumor and antimetastatic activity of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470), a semisynthetic analogue offumagillin, was evaluated in breast cancer cell lines. In an in vitro MTTassay, after 72 hrs continuous exposure to TNP-470, growth inhibition wasobserved in all seven cell lines of murine (JYG-A, JYG-B, DD-762, andBALB/c-MC) or human (KPL-1, MDA-MB-231, and MKL-F) origin, in which the50% inhibitory concentrations (IC50) at 72 hrstreatment were 4.6, 4.4, 4.6, 10.1, 35.0, 25.3, and 33.4 µg/ml,respectively. In an in vivo assay using JYG-A, JYG-B, KPL-1, and MDA-MB-231cells by orthotopic (right thoracic mammary fat pad) transplantation infemale nude mice, TNP-470 at 30 or 50 mg/kg body weight was injected s.c.every other day from the day of tumor cell inoculation until the end of theexperiment. The inhibitory effect on primary tumor growth was obtained inall four cell lines in a dose-dependent manner. In the 50 mg/kgTNP-470-treated group, the reductions in tumor weight of the JYG-A, JYG-B,KPL-1, and MDA-MB-231 cells with respect to the controls were 50%,30%, 4%, and 49%, respectively. Metastasis was seen inthe JYG-A, JYG-B, and KPL-1 cells. The numbers of mice bearing pulmonarymetastases of JYG-A and JYG-B cells and regional axillary lymph nodemetastases of KPL-1 cells were reduced, and TNP-470 at the 50 mg/kg dose toKPL-1 cells significantly reduced lymph node metastases compared with thecontrol. Although the weight gain was retarded in the TNP-470-treated mice,weight loss was not seen. TNP-470 was highly effective in the treatment ofbreast cancer cells. These results suggest that the clinical use of TNP-470may be a promising treatment for breast cancer patients. 相似文献
899.
The field of molecular genetics continues to see an ever increasing number of applications to pediatric tumor analysis. Studies
in pediatric tumors have identified novel genes and other genetic changes, a large number of which reflect one of the following
mechanisms: (1) activation of proto-oncogenes; (2) loss of tumor suppressor genes; or (3) creation of novel fusion proteins. At least one of these mechanisms is operational in each of the following pediatric tumors:
neuroblastoma, Ewing sarcoma and peripheral primitive neuroectodermal tumor (pPNET), intra-abdominal desmoplastic small-cell
tumor, rhabdomyosarcoma, synovial sarcoma, and Wilms tumor. Out of this research has come not only an increased understanding
of oncogenesis but also, for each of the tumors listed above, diagnostic and/or prognostic markers that can be used by the
pathologist and oncologist to improve overall patient management.
Received November 20, 1997; accepted April 20, 1998. 相似文献
900.
Primary Mitral Valve Sarcoma in Infancy 总被引:2,自引:0,他引:2
K. Itoh T. Matsumura Y. Egawa M. Watanabe T. Ohshio A. Ohta Y. Hayabuchi K. Seki 《Pediatric cardiology》1998,19(2):174-177
Primary cardiac sarcoma is a rare tumor, found especially in children, particularly in the left side of the heart. This report
describes a rare case of primary mitral valve sarcoma in a 7-month-old male infant with hemiparesis and heart murmur who underwent
mitral valve replacement because of excessive invasion of the mitral valve by the tumor. The patient remains well, free of
recurrence and cerebral metastasis, and without adjuvant therapy 18 months after the operation. 相似文献